Clinical Trial Update: A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of combining ibrutinib with nivolumab in participants with hema…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms

Drugs mentioned

• Ibrutinib (ibrutinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hematologic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-15